Skip to content
  • Sunday, 26 July 2026
  • 2:10 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Johnson & Johnson’s Spravato Remission Data Takes Center Stage in Push for Treatment-Resistant Depression Growth
Laboratory Automation & Robotics

Johnson & Johnson’s Spravato Remission Data Takes Center Stage in Push for Treatment-Resistant Depression Growth

Lana Keisha Jul 19, 2026 0

A recent poster presentation at Psych Congress Elevate by Johnson & Johnson has placed esketamine nasal spray, marketed as Spravato,…

Read More
Laboratory Automation & Robotics

J&J Positions Spravato Remission Data at Forefront of Treatment-Resistant Depression Growth Strategy

Lana Keisha Jul 12, 2026 0

Johnson & Johnson (J&J) is intensifying its marketing efforts for Spravato (esketamine) by spotlighting compelling remission rate data for treatment-resistant…

Read More
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jul 5, 2026 0

More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in 1962 while diligently searching for a safer…

Read More
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jun 27, 2026 0

More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in a quest for a safer anesthetic, the…

Read More
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jun 20, 2026 0

Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…

Read More
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jun 13, 2026 0

More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule…

Read More
Stem Cell & Regenerative Medicine

How breast cancer cells survive in bone marrow after remission

Dwi Wanna May 27, 2026 0

The Challenge of Estrogen Receptor-Positive Breast Cancer Estrogen receptor-positive (ER+) breast cancer represents approximately 70% to 80% of all breast…

Read More
Stem Cell & Regenerative Medicine

How breast cancer cells survive in bone marrow after remission

Dwi Wanna May 19, 2026 0

The Hidden Threat of Estrogen Receptor-Positive Breast Cancer Estrogen receptor-positive (ER+) breast cancer is the most prevalent form of the…

Read More
Stem Cell & Regenerative Medicine

How breast cancer cells survive in bone marrow after remission

Dwi Wanna Apr 18, 2026 0

The study, published in the Journal of Clinical Investigation, identifies a sophisticated "smuggling" operation between cancer cells and the bone…

Read More
University of Basel Researchers Engineer First Fully Human Synthetic Bone Marrow Model to Advance Cancer Research and Reduce Animal TestingForests Worldwide Face Unforeseen Disruption as Nitrogen Pollution Alters Ancient Carbon CycleSai Life Sciences Plans to Recruit 700+ Professionals in FY27 as Indian CRDMO Demand AcceleratesUnifying Genetic Pathways: Shared Genes Hold Promise for Future Human Limb Regeneration
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ